The Asian market was favorable to the rising price trends of titanium dioxide in the first quarters of 2023. The prices inclined gradually with some slight fluctuations. The positive outlook of the market was a direct effect of removing covid restrictions, upscaling industrial production, and high speed of market recovery.

For a mini-review published in the journal Particle and Fibre Technology in 2021, scientists wanted to evaluate whether Ti02 particles contributed to the development and/or exacerbation of irritable bowel disease, and whether they altered the four elements of intestinal barrier function: the intestinal microbiota, the immune system, the mucus layer, and the epithelium. The breakdown of these four elements can contribute to autoimmune, neurological, inflammatory, infectious, and metabolic diseases. Following their review, the researchers concluded: “Data indicate that TiO2 is able to alter the four compartments of IBF and to induce a low-grade intestinal inflammation associated or not with pre-neoplastic lesions.” 

BaSO4 + 4C=BaS + 4CO

A 2022 review on past studies of titanium dioxide and rat lung cancer, for instance, said the original study was under extreme conditions and its effects were not replicated in other animal species. Additionally, the review concluded that the few studies which did directly focus on titanium dioxide's impact on humans did not end up showing any increased cancer risk.

In May 2021, the European Food Safety Authority (EFSA) published an opinion that stated that titanium dioxide can no longer be considered safe when used as a food additive.